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The well-known antiparasitic compound licochalcone A is a potent membrane-active agent that transforms
normal erythrocytes into echinocytes in parallel with the inhibition of growth of Plasmodium falciparum
cultures, the in vitro antiplasmodial effect apparently being an indirect effect on the host cell. In vitro
experiments with synchronous cultures demonstrate that inhibition of invasion is the principal mechanism of
growth inhibition. The erythrocyte membrane-modifying effect was also transiently observed in vivo in mice
after intravenous administration.
Licochalcone A (Fig. 1) was originally isolated (39, 44) as a
constituent of roots and rhizomes of various species of Glycyr-
rhiza L. (licorice root), and its structure was confirmed by
synthesis (20, 22, 44). Subsequent studies resulted in reports of
a variety of biological effects of licochalcone A, notably anti-
bacterial (13–15, 17, 18, 36, 43), antileishmanial (3, 4, 8, 34, 45,
46), and antiplasmodial (6, 7, 23) ones. Thus, the compound
inhibited growth of Plasmodium falciparum strain 3D7 para-
sites in vitro with 50% inhibitory concentrations (IC50s) of
5.6  0.6 M (35) and reduced parasitemia in mice infected
with Plasmodium yoelii (7, 23). Compounds related to licoch-
alcone A exhibited comparable antiplasmodial activity in vitro
(5, 35).
The licochalcone A used in the present work was synthesized
as previously described (22, 33, 44). The purity of the com-
pound was assessed by high-performance liquid chromatogra-
phy (C18 column, acetonitrile gradient in water) and 600-MHz
1H nuclear magnetic resonance and was higher than 99.9%.
Determination of the in vitro IC50 (Fig. 2) for P. falciparum
strain 3D7 (initial parasitemia, 1.5%) was performed as previ-
ously described (49) using 12 concentrations (each used in
triplicate) in the range from 0.098 to 25.0 g/ml (0.29 to 73.9
M); an average IC50 calculated from three independent de-
terminations was 2.10  0.56 g/ml (6.21  1.65 M), which
was practically identical to the reported value (35). Micro-
scopic examination of the cultures showed the presence of
dead merozoites and ruptured schizonts at concentrations of
1.56 g/ml and above, and no internal parasites beyond the
ring stage were observed.
However, simultaneously with the growth inhibition, the ex-
posure of the parasite cultures to licochalcone A caused pro-
nounced membrane perturbations of the erythrocytes in which
the parasites grow. The effect of licochalcone A on erythro-
cytes was the same regardless of whether parasitized or non-
parasitized erythrocytes were used and was observed in the
same concentration range as that of the in vitro antiplasmodial
activity. In order to assess these membrane effects systemati-
cally, nonparasitized erythrocytes were incubated with licochal-
cone A at five different concentrations (0.098, 1.56, 3.13, 5.0,
and 25.0 g/ml) for 48 h as in the growth inhibition assay. The
deformations of the cell shape were investigated by light mi-
croscopy after fixation to glass slides with methanol followed
by staining with Giemsa as well as by the hanging drop tech-
nique, by differential interference contrast microscopy after
fixation on glass slides with glutaric aldehyde, and by transmis-
sion electron microscopy (TEM) using standard methods (49).
Control experiments and cultures containing 0.098 g of lico-
chalcone A/ml showed a normal discocytic shape of erythro-
cytes. In agreement with previous studies (49), dimethyl sul-
foxide (DMSO) present in the medium in concentrations up to
0.5% caused no change of the erythrocyte shape. At licochal-
cone A concentrations in the range of 1.56 to 5.0 g/ml, the
discocytes were transformed to echinocytes, with type III echi-
nocytes (2) dominating. The shape changes were increasingly
pronounced as the concentration increased, with concomitant
formation of an increasing number of exovesicles. All micro-
scopic techniques used in this study showed consistent results
demonstrating that the observations are not related to sample
preparation. The results of the TEM investigations are shown
in Fig. 3. Interestingly, the erythrocytes treated with 25.0 g of
licochalcone A/ml (the highest concentration tested) showed
more normal cell shapes and even slightly stomatocytic forms
(Fig. 3). That the observed membrane shape changes are in-
dependent of the presence of P. falciparum parasites was dem-
onstrated in a parallel series of experiments with parasitized
* Corresponding author. Mailing address: Department of Medicinal
Chemistry, The Danish University of Pharmaceutical Sciences, Uni-
versitetsparken 2, DK-2100 Copenhagen, Denmark. Phone: 45-3530-
6372. Fax: 45-3530-6040. E-mail: jj@dfuni.dk.
4067











erythrocytes (initial parasitemia of 1.5%, incubation time of
48 h, licochalcone A concentration of 0.098 to 25.0 g/ml).
In order to investigate the time course of the membrane
effects of licochalcone A, nonparasitized erythrocytes were
treated with 0, 0.2, 2.0, 10.0, and 25.0 g/ml of the compound,
and the cells were examined by light microscopy after 5, 15,
and 30 min and 1, 2, 4, 24, 30, and 48 h. This experiment
demonstrated that the uptake of licochalcone A into the eryth-
rocyte membrane and the resulting cell shape deformations
take place within 5 min, after which the membrane effects were
essentially time independent in the concentration range up to
10.0 g/ml. By contrast, the erythrocytes treated with 25.0 g
of licochalcone A/ml showed formation of type III echinocytes
within 5 min, whereas the above-mentioned return to disco-
cytic or slightly stomatocytic forms was complete only after
24 h. When the erythrocytes were preincubated with 5 g of
licochalcone A/ml for 24 h and concentration of the compound
in the medium increased to 25.0 g/ml, the time course of the
membrane shape changes (assessed after 15 and 30 min and 1,
4, 24, 30, and 48 h of additional incubation time) was exactly
the same as when the cells were directly exposed to 25.0 g of
licochalcone A/ml. On the other hand, dilution of an erythro-
cyte culture incubated for 24 h with 25.0 g of licochalcone
A/ml with medium, resulting in a decrease of the concentration
to 5.0 g/ml, did not result in a return to the echinocyte III
shape. This shows that the cell shape change induced by 25.0
g of licochalcone A/ml, and hence the resulting membrane
loading, is irreversible under these conditions.
In order to determine which developmental stage of the
parasite is susceptible to the presence of licochalcone A in the
erythrocyte membrane, cultures synchronized by use of mag-
netic cell sorting were used (42). Thus, the late-stage parasites
were separated, transferred to flasks with the growth medium,
and allowed to develop to ring stages or to trophozoites. The
synchronous cultures were then treated with 0.098, 1.56, 3.13,
5.0, and 25.0 g of licochalcone A/ml, and the effect on the
growth was monitored by light microscopy.
The control culture starting with ring stages showed late
trophozoites (and a few schizonts) after 24 h and rings (and a
few merozoites) after 48 h. The cultures treated with 5.0 or
25.0 g of licochalcone A/ml showed only a few early tropho-
zoites after 24 h, and those treated with 0.098 to 3.13 g/ml
contained trophozoites and schizonts. After 48 h the culture
treated with 25.0 g of licochalcone A/ml showed only a few
early trophozoites and internal undeveloped merozoites. The
culture treated with 3.13 and 5.0 g of licochalcone A/ml
showed a few late trophozoites, schizonts, and merozoites. The
cultures treated with the lowest concentrations of the com-
pound contained a lot of ring stages. The control culture start-
ing with trophozoites contained ring stages (and a few ruptured
schizonts) after 24 h and rings and trophozoites after 48 h.
Treatment with 5.0 or 25.0 g of licochalcone A/ml resulted in
the presence of mainly trophozoites and a few undeveloped
internal parasites after 24 h. The culture treated with 3.13
g/ml showed the presence of equal amounts of trophozoites
and rings. The cultures treated with 0.098 or 1.56 g of lico-
chalcone A/ml were similar to the control. After 48 h, in all the
cultures the number of internal parasite stages was strongly
diminished (in a concentration-dependent manner), and exter-
nal and internal undeveloped merozoites were present. These
experiments demonstrate that the most significant growth in-
hibition is observed when the culture goes through the eryth-
rocyte invasion stage and that the extent of inhibition parallels
the extent of erythrocyte membrane modification, as in the
experiments with asynchronous cultures (Fig. 2).
Since licochalcone A was reported to decrease parasitemia
in mice infected with P. yoelii (7), it was of interest to assess
possible effects of the compound on the erythrocyte morphol-
ogy in vivo. Three administration routes were tested: oral,
intraperitoneal, and intravenous. For oral administration, mice
(20 to 25 g, three mice per dose) were administered 0, 20, or
100 mg of licochalcone A/kg of body weight in olive oil (5 l/g
of body weight of a solution containing 0, 4, or 20 mg of
licochalcone A/ml, obtained by 3:17 dilution of stock solutions
in DMSO with olive oil). For intraperitoneal administration,
mice (25 to 30 g, three mice per dose) were administered 0, 10,
or 50 mg of licochalcone A/kg in saline containing Brij 35 (10
l/g of body weight of a solution containing 0, 1, or 5 mg of
licochalcone A/ml, obtained by 3:37 dilution of stock solutions
in DMSO with 5% Brij 35 in saline). For intravenous admin-
istration, mice (25 to 30 g, three mice per dose) were admin-
istered 0, 10, or 25 mg of licochalcone A/kg; the compound was
injected into a tail vein either as 0.75 l/g of body weight of a
solution in DMSO (0, 13, or 33 mg/ml) or as 5 l/g of body
weight of a solution in 5% Brij 35 in saline (0, 2, or 5 mg/ml).
Control mice were administered the vehicles alone. Solutions
FIG. 1. Chemical structure of licochalcone A.
FIG. 2. Example of inhibition curve showing licochalcone A inhi-
bition of growth of P. falciparum strain 3D7 cultured in human eryth-
rocytes, as expressed by incorporation of [3H]phenylalanine (49). In
this particular determination, an IC50 of 2.02  0.19 g of licochalcone
A/ml (5.97  0.56 M) is obtained. The IC50 of chloroquine diphos-
phate determined under identical conditions was 28.3  13.2 ng/ml or
0.055  0.025 M.
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for the intraperitoneal and intravenous administrations were
subjected to sterile filtration prior to use. Blood samples were
withdrawn from the eye 1 h and 24 h after the administration,
smears were prepared, and the erythrocyte shapes were as-
sessed microscopically.
Neither of the above experiments demonstrated deviations
from the normal discocytic erythrocyte shape in the eye blood.
However, while the mice subjected to peroral or intraperito-
neal administration showed normal behavior, those subjected
to the intravenous administration were clearly disturbed by the
administration of licochalcone A (but not of the vehicles
alone), especially at the highest doses (symptoms included
fatigue, increased heartbeat rate, and abnormal walking).
Therefore, additional experiments using the intravenous ad-
ministration route were performed. Thus, two mice (20 to 25 g)
received 25-mg/kg licochalcone A in DMSO (0.75 l/g), two
mice received 25-mg/kg licochalcone A in 5% Brij 35 in saline
(5 l/g), and two groups of two control mice received the
vehicles alone via the tail vein. Blood was withdrawn from the
eye and the tail immediately after the administration and from
the eye 5 min after the administration. The circulated blood,
sampled from the eye immediately after administration of li-
cochalcone A in either of the two vehicles, contained type II
and III echinocytes (2) as the dominating cell form, with only
a few discocytes present. The blood sampled locally from the
tail showed more pronounced alterations and the presence of
spheroechinocytes (2). No erythrocyte shape changes occurred
after intravenous administration of the vehicles alone (0.75 l
FIG. 3. TEMs (magnification, 2,000) illustrating effects of licoch-
alcone A on erythrocyte membrane. (A) Control erythrocytes incu-
bated for 48 h in medium containing 0.5% DMSO. (B-E) Erythrocytes
incubated for 48 h with medium containing 1.56, 3.13, 5.0, and 25.0 g
of licochalcone A/ml, respectively.
VOL. 48, 2004 NOTES 4069











of DMSO or 5 l of 5% Brij 35 in saline per g of body weight).
In the circulated blood sampled from the eye 5 min after the
administration of licochalcone A, only mild erythrocyte shape
alterations were apparent, with discocytes and type I echino-
cytes (2) as the dominating cell shapes.
The present experiments demonstrate that licochalcone A is
a potent membrane-active agent, causing rapid and concentra-
tion-dependent transformation of discocytes into echinocytes
(Fig. 3) paralleling the antiplasmodial activity (Fig. 2). The
effect could also be transiently observed in vivo after intrave-
nous administration of the compound, but the cells returned
quickly to the normal shape, presumably as the result of redis-
tribution of licochalcone A in lipophilic compartments of the
body or removal of damaged erythrocytes. It is well docu-
mented that the discocyte-to-echinocyte transformations are
caused by incorporation of chemicals into the outer layer of the
lipid bilayer of the erythrocyte membrane (2, 19, 28, 41). Thus,
rapid and concentration-dependent transformation of disco-
cytes to echinocytes accompanied by exovesiculation has been
observed with a number of amphiphiles and other compounds
(16, 21, 47). The partial return of the cell shape to normal at
very high licochalcone A concentrations (25.0 g/ml) can be
explained by redistribution of the compound into the inner
membrane layer (21, 47); although the cells acquire a more
normal shape, it is obvious that also at this concentration the
erythrocyte membrane is loaded with licochalcone A. While
the initial uptake of licochalcone A into the erythrocyte mem-
brane is relatively fast (up to 5 min), the redistribution ob-
served at high concentrations is slow (up to 24 h).
At the same time, the experiments with synchronous cul-
tures strongly suggest that the major effect of licochalcone A is
inhibition of erythrocyte invasion by merozoites and/or inhibi-
tion of initial growth of internalized merozoites. The invasion
and growth of P. falciparum in erythrocytes depend on the
normal function and integrity of the erythrocyte membrane; as
it grows inside the erythrocyte, the parasite causes extensive
modifications of the host cell, including rearrangement of the
host cell’s macromolecules, expression of large numbers of its
own proteins, and establishment of new permeation pathways
(9, 10, 25). Modifications of the erythrocyte membrane com-
position, expressed as the echinocyte formation, are thus ex-
pected to cause conditions unfavorable for the in vitro prolif-
eration of the parasite. There is indeed a lot of evidence
emphasizing the importance of the erythrocyte membrane
state and composition for the parasite’s growth (11, 24, 26, 31,
32, 37, 40). We have recently demonstrated that a variety of
compounds inhibit in vitro growth of P. falciparum by virtue of
their incorporation into the erythrocyte membrane (1, 47–49).
The described correlation between the echinocytogenic and in
vitro antiplasmodial effects of licochalcone A provides a novel
example of this effect. We believe that the observations re-
ported herein are of profound interest in relation to the cur-
rent efforts to develop chalcones as novel antimalarial drugs (5,
6, 12, 23, 27, 29, 30, 35, 38), in part because the in vitro assay
with chalcones presumably provides information about struc-
ture-activity relationships for the erythrocyte membrane-mod-
ifying effect rather than for a direct antiparasitic effect, and in
part because of expected problems with intravenous adminis-
tration of the drug. With respect to the reported in vivo anti-
malarial activities of chalcones, we note the prevalent lack of
correlation between IC50s for chalcones and chloroquine in
vitro (P. falciparum) and their relative effects in vivo (mouse
models employing Plasmodium berghei and P. yoelii) (7, 12, 30,
38). While the latter discrepancy has yet to be explained, the
erythrocyte membrane changes described for the first time in
this work are a convenient means of identification of possible
artifacts due to host-cell effects of chalcones during in vitro
antiplasmodial screens. In addition, the membrane activity of
licochalcone A may be a significant factor in other in vitro
assays employing whole cells.
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